Lake Street Capital Issues Pessimistic Forecast for MDxHealth (NASDAQ:MDXH) Stock Price

MDxHealth (NASDAQ:MDXH) had its price target decreased by analysts at Lake Street Capital from $9.00 to $5.00 in a report released on Thursday,Benzinga reports. The firm currently has a “buy” rating on the stock. Lake Street Capital’s price objective suggests a potential upside of 407.77% from the stock’s previous close.

A number of other research firms have also recently weighed in on MDXH. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of MDxHealth in a research report on Friday, March 27th. TD Cowen restated a “buy” rating and issued a $1.50 price objective (down from $7.00) on shares of MDxHealth in a report on Thursday. BTIG Research reduced their price objective on shares of MDxHealth from $7.00 to $4.00 and set a “buy” rating on the stock in a report on Thursday. Finally, William Blair lowered shares of MDxHealth from an “outperform” rating to a “market perform” rating in a research note on Thursday. Four investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, MDxHealth has a consensus rating of “Moderate Buy” and a consensus price target of $4.63.

MDxHealth Stock Down 49.5%

Shares of MDxHealth stock traded down $0.97 during mid-day trading on Thursday, hitting $0.98. The stock had a trading volume of 10,868,031 shares, compared to its average volume of 297,605. The firm has a 50-day moving average of $2.52 and a two-hundred day moving average of $3.27. MDxHealth has a 12-month low of $0.94 and a 12-month high of $5.33. The firm has a market cap of $48.74 million, a P/E ratio of -1.47 and a beta of 1.60.

MDxHealth (NASDAQ:MDXH) last posted its quarterly earnings results on Wednesday, May 13th. The company reported ($0.19) earnings per share for the quarter, missing the consensus estimate of ($0.14) by ($0.05). The firm had revenue of $23.90 million during the quarter, compared to analysts’ expectations of $30.89 million. MDxHealth had a negative net margin of 31.07% and a negative return on equity of 1,078.01%. Sell-side analysts expect that MDxHealth will post -0.41 earnings per share for the current year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of MDXH. Intesa Sanpaolo Wealth Management purchased a new stake in shares of MDxHealth in the fourth quarter valued at about $36,000. Lido Advisors LLC purchased a new stake in MDxHealth during the third quarter worth about $48,000. GSA Capital Partners LLP purchased a new stake in MDxHealth during the third quarter worth about $48,000. Squarepoint Ops LLC acquired a new position in MDxHealth during the fourth quarter worth about $51,000. Finally, Jefferies Financial Group Inc. purchased a new stake in shares of MDxHealth in the third quarter valued at about $53,000.

MDxHealth News Roundup

Here are the key news stories impacting MDxHealth this week:

• Positive Sentiment: BTIG Research kept a Buy rating on MDxHealth, even while cutting its price target to $4.00 from $7.00, implying upside from current levels. BTIG price target update
• Neutral Sentiment: The company’s Q1 2026 earnings call transcript and highlights were published, giving investors more detail on management’s commentary and strategic priorities. Q1 2026 earnings highlights
• Neutral Sentiment: MDxHealth also released its full Q1 2026 results and conference call materials, which may help investors gauge execution and the company’s revenue trajectory. Q1 2026 results transcript
• Negative Sentiment: William Blair downgraded MDxHealth from Outperform to Market Perform, signaling reduced conviction in the near-term outlook. William Blair downgrade
• Negative Sentiment: Q1 2026 results missed expectations, with EPS of -$0.19 versus -$0.14 expected and revenue of $23.9 million versus $30.9 million expected, increasing concern about growth and profitability. Earnings miss details
• Negative Sentiment: Management’s FY2026 revenue guidance of $110 million to $115 million came in below the consensus estimate of $122.6 million, which likely added pressure to the stock. FY2026 guidance

About MDxHealth

MDxHealth, headquartered in Mechelen, Belgium, with a U.S. presence in Newton, Massachusetts, is a molecular diagnostics company focused on improving the accuracy of cancer diagnosis and treatment decision making through epigenetic biomarker assays. The company specializes in developing and commercializing tests that detect DNA methylation changes associated with urological cancers, enabling more precise risk stratification and patient management.

MDxHealth’s lead product portfolio includes ConfirmMDx and SelectMDx.